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INTRODUCTION
Respiratory disease is a broader concept that includes any pathology 
affecting airways or any of its structures and organs[1]. Also, the 
pathologies affecting human respiration have a wide range on its 
aetiologies, from environmental, namely viral or bacterial infections 
and different sources and sorts of pollution or allergens, until genetic 
causes, together with a more or less complex admixture of both[2,3,4]. 
Contributing as well for its conceptual amplitude is the extensive 
gradient of severity levels that the multiple respiratory diseases 
assume, from simple flu and cough to chronic and severe pathologies. 
Accordingly to the World Health Organization, chronic respiratory 
diseases affect hundreds of millions worldwide, being asthma, with 
300 millions, and chronic obstructive pulmonary disease (COPD), 
with 210 millions, the most prevalent[5]. However, lower respiratory 
infection diseases are one of the leading causes of death on the world, 
assuming the fourth position, after COPD, with the responsibility for 
3.1 million lives lost in 2012[6].
    Since it is an outside open system, respiratory tract is a privileged 
way to pathogens entry into the body. However, despite this 
vulnerability and mostly because of it, one of the immune system 
defence first lines is precisely located in the respiratory system, 
especially in epithelium airways, in order to protect it, and the entire 
organism, from infections. When the inhaled foreign organisms 
contact with the airway epithelium they are confronted with a 
protective arsenal that ranges from physical barriers and antimicrobial 
compounds until immune receptors, which lead to the production of 
cytokines and chemokines that may affect microorganisms directly 
but also recruit immune cells[7]. On the development of respiratory 
infectious diseases, host genetics play an important role. In fact, since 
the organism ability to oppose to any outside aggression is greatly 
influenced by its genetic characteristics, especially those defining the 
immune system structure and function, the susceptibility to viral or 
bacterial respiratory infections would be, at least partially, defined 
by its genome[8,9]. Despite often providing conflicting results, several 
studies identified and evaluated hundreds of candidate-genes for 
respiratory infectious disease susceptibility and, among those, several 
genetic markers were confirmed has been positively associated[10,11].
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ABSTRACT
The HLA system harbour a wide set of genes that plays an important 
role in the regulation and action of the immune system against 
invading pathogens, making them natural candidates for research 
on the genetic susceptibility for respiratory infections. Thus, along 
past decades, this topic has been subject to intense research and, 
consequently, several alleles of those loci have been implicated in 
the ability, more or less effective, to tackle and control invading 
pathogens in the respiratory system. Current editorial introduce, 
revise, summarize and comment the major advances in the role 
of HLA genes for the development of, and protection against, 
respiratory infectious disease. A general picture is drawn and new 
challenges on the field are relocated, especially those that might 
enlighten respiratory diseases aetiology and, thus, contribute in 
advances for diagnosis and treatment.
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emphasize their role in immune modulation and protection against 
NK lysis[28,29]. In opposition to the ubiquitous expression of classical 
class I, these non-classical loci tend to be conditional and tissue 
or organ specific[30]. HLA-E molecules act on both the innate and 
adaptive immune system playing a key role in their modulation[31,32]. 
HLA-E is represented by only 7 non-synonymous alleles (IMGT/
HLA Database, release 3.22.0, 2015-10-10) and, even so, only two 
of them (E*01: 01 and E*01: 03) have been show to express relevant 
molecules for the immune function[33]. These HLA-E molecules 
are broadly expressed on all cells[34], presenting in the healthy cells 
surface a limited set of highly conserved peptides derived from 
classical HLA class I[35]. HLA-E molecules and its binding peptides 
constitute complexes that act as ligand for both inhibitory (NKG2A/
CD94) and stimulatory (NKG2C/CD94) receptors in NK cells 
and in a subset of CD8+ T cells[36,37]. Through this mechanism, 
NK cells monitor the HLA expression that is occurring inside 
the cell and, thus, evaluate its health status[38]. A change in the 
complexes constituted by HLA-E and its binding peptides prevent 
the connection with the NK inhibitory receptor (NKG2A/CD94), 
which triggers a cytotoxic response against the unhealthy cell[39]. 
HLA-F is also a very low polymorphic locus with only 4 proteins 
expressed (IMGT/HLA Database, release 3.22.0, 2015-10-10) and 
its expression and function patterns still under investigation. Despite 
expressing at cell surface at specific conditions and in particular cells, 
namely in activated lymphocytes, its most common expression is 
cytoplasmic[40,41]. HLA-F seems to be expressed in the first moments 
of the activation of an immune response and the evidences of its 
unusual properties, e.g., independent pathway to reach cell surface[42] 
and ability to bind bigger peptides[43], point out for a different 
biological function than that of other class I molecules. HLA-G is 
better studied and despite its low polymorphism it’s higher than 
other non-classical class I. With 51 alleles found worldwide, HLA-G 
locus expresses 17 distinct functional proteins and, due to alternative 
splicing, can assume membrane-bound and soluble isoforms (IMGT/
HLA Database, release 3.22.0, 2015-10-10)[44]. Its functions are 
oriented towards immune inhibition and tolerance and one of its 
most known implications is on the prevention of maternal-foetal 
rejection)[45]. Cells from placenta migrate into the maternal uterus 
and produce both membrane and soluble HLA-G isoforms, which 
will inhibit maternal immune response against foetal foreign antigens 
through interaction with inhibitory receptors in maternal leukocytes, 
establishing an immune privilege[30]. This mechanism of inhibition 
and tolerance mediated by HLA-G has revealed to be involved 
in tumour escape from the immune system and, in fact, a higher 
expression has been significantly correlated with poor prognosis in 
patients with solid tumours)[46,47,48].
    Among the tens of non-HLA genes located on class I region, is 
worth mentioning the two functional MIC (MHC class I-related 
chain) genes (MICA and MICB). MICA and MICB are located 
between HLA-B and the centromeric end side of the class I region 
and, despite showing low homology with classical HLA genes, 
they are also highly polymorphic and express as membrane bound 
glycoproteins or soluble forms. In opposition to HLA, these 
glycoproteins don’t combine with β2-microglobulin, do not bind 
peptides and are not expressed on normal circulating lymphocytes[49]. 
MICA and MICB are ligands of the natural killer (NK) and T cells 
receptor NKG2D (natural-killer group 2, member D), and both 
express under stress conditions to activate an immune response[50].
    The HLA class II genes are located on the most centromeric region 
of the human MHC and it includes alpha and beta chain genes, the 
classical HLA-DPA, -DPB, -DQA, –DQB, -DRA and –DRB, and 
THE HLA SYSTEM
Since the human Major Histocompatibility Complex (MHC), known 
also as the Human Leukocyte Antigen (HLA) region, harbours a 
wide set of genes that play an important role in the regulation and 
action of the immune system against invading pathogens, it is not 
surprising that several alleles of those loci have been implicated in 
the ability, more or less effective, to tackle and control infections 
in the respiratory system[12,13,14]. The HLA system is located in 
the short arm of chromosome 6 (6p21.3), along approximately 4 
megabases, and it constitutes an intricate and interrelated cluster 
of genes involving more than 300 loci, from which at least 160 are 
functional genes[15,16]. These functional genes are considered the most 
polymorphic of the human genome and about 40% of them have an 
important role in the regulation and action of the immune system[12,17]. 
Accordingly to the structure and function of its genes, the human 
MHC has been classified in three main regions: class I, class II and 
class III; and despite it is known as HLA system, most of the genes 
enclosed in each region are non-HLA. The class I are located on the 
most telomeric region of the human MHC and, besides a majority of 
non-HLA genes, it includes 3 high polymorphic HLA genes, known 
as classical (Class Ia: HLA-A, HLA-B and HLA-C) and 3 low 
polymorphic HLA genes, known as non-classical (class Ib: HLA-E, 
HLA-F and HLA-G), besides a dozen of HLA pseudogenes and one 
HLA non-coding gene[18]. 
    HLA class I loci express molecules composed by a heavy chain 
that bound non-covalently to a light chain, a β-2 microglobulin 
encoded by B2M gene located on chromosome 15. The heavy 
chain is structured in three domains (α1, α2 and α3) together with a 
membrane-spanning region and a cytoplasmic tail[19]. Classical HLA 
class I genes express cell-surface glycoprotein molecules on almost 
all nucleated cells, playing an important role in “self” and “non-
self” immune recognition. These molecules display at cell surface 
small protein fragments almost originated in the cytosol. Their 
interaction with inhibitory or activating receptors from the surface of 
Natural Killer (NK) or cytotoxic CD8+ T-cells modulates the lytic 
activity. As a result, when a cell expresses foreign proteins, due to 
a viral infection, or shows a different expression pattern, due to an 
oncogenesis process, HLA class I signals those changes through its 
own binding to the resulting peptides and, after recognition by NK 
or CD8+ T cells, an immune response is triggered[20,21,22]. This same 
immune mechanism is responsible for allograft rejection when HLA 
compatibility between donor and recipient is missing[23]. HLA-B 
is the most polymorphic classical class I gene, with 4077 alleles 
indentified to date in the different human populations, followed 
by HLA-A (3285 alleles) and HLA-C (2801 alleles) (IMGT/HLA 
Database, release 3.22.0, 2015-10-10). Despite each HLA variant 
has a singular structure in its peptide-binding groove, the number 
of small peptides that can bind to each one is large[24]. Additionally, 
the high polymorphism that classical class I HLA shows improves 
the ability of the immune system to recognise a wider range of 
pathogens. As so, since heterozygosity at any of the classical class I 
loci are associated with positive outcomes during immune infections, 
these polymorphisms have been driven by selection to improve the 
efficacy of the immune system[25,26,27]. 
    Non-classical class I loci (HLA-E, HLA-F and HLA-G) are best 
known for their participation on the regulation of the innate immunity 
but they can also play a role in regulating adaptive responses. 
HLA-E, -F and –G co-express in the placenta trophoblast cells and 
several studies have shown a poor prognosis associated to their 
higher expression in different types of malignant tumours, facts that 
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also the non-classical HLA-DMA, –DMB, -DOA and –DOB, besides 
some pseudogenes and nonHLA genes[18]. The alpha and beta chains 
expressed by the classical class II genes associate each other non-
covalently to compose heterodimer transmembranar molecules 
on the surface of a restricted set of cells that interact with CD4+ 
T-helper cells, predominantly antigen-presenting cells (APC) such as 
macrophages, dendritic cells and B lymphocytes[51]. Both alpha and 
beta chains contribute to form the peptide binding groove and those 
peptides presented by HLA class II molecules on the cell surface of 
APC result from internalized and processed exogenous antigens that 
could derive from cell surface proteins, soluble proteins or proteins 
from a virus, bacteria or protozoa invaders[52]. When CD4+ T-helper 
cells become activated, after recognizing a foreign peptide presented 
within the antigen binding groove of a class II molecule, they 
differentiate and secrete cytokines which influence the proliferation, 
function and differentiation of other immune cells, including other 
T cells, B cells and macrophages, triggering an adaptive immune 
response against foreign pathogens or allograft[53]. HLA-DR loci code 
for the DR heterodimer molecule, with the low polymorphic HLA-
DRA1 gene expressing the alpha chain and the high polymorphic 
HLA-DRB1 gene the beta chain[18]. Besides the ubiquitous DRB1, 
other lowest polymorphic HLA-DRB loci could also be present in a 
variable number, namely -DRB3, -DRB4, and -DRB5 coding genes 
and several others non-coding genes (-DRB2; -DRB6; -DRB7; 
-DRB8 and -DRB9)[54]. HLA-DRA1, the sole gene expressing the 
alpha chain of DR molecules, is the less polymorphic class II locus 
with 7 alleles coding for only 2 different proteins. Otherwise, HLA-
DRB1 is the most polymorphic class II locus with 1825 alleles that 
express 1335 different proteins in all human studied populations. The 
genes that express the other two classical class II molecules, HLA-
DQ and -DP, show also a high asymmetry in the polymorphisms of 
alpha and beta chains. In fact, if we compare the HLA-DQA1, with 
54 alleles and 32 expressed proteins, with the HLA-DQB1, with 
876 alleles and 595 expressed proteins, and the HLA-DPA1, with 
42 alleles and 21 expressed proteins, with the HLA-DPB1, with 
587 alleles and 480 expressed proteins, this asymmetry is blatantly 
obvious. (IMGT/HLA Database, release 3.22.0, 2015-10-10).
    The non-classical class II proteins, HLA-DM and -DO, assume 
the same structure described above for classical class II but lacks 
the ability to bind peptides. Their heterodimer molecules are 
also expressed by alpha and beta chain genes, HLA-DMA1 and 
-DMB1 for -DM molecules, and HLA-DOA1 and -DOB1 for -DO 
molecules[55,56]. However, in these non-classical loci, alpha and beta 
chain genes polymorphisms asymmetry are not evident and both 
show a very low number of alleles. To date, 7 alleles and 4 expressed 
proteins were found for HLA-DMA1, 13 alleles and 7 expressed 
proteins for HLA-DMB1, 12 alleles and 3 expressed proteins for 
HLA-DOA1, and 13 alleles and 5 expressed proteins for HLA-DOB1 
(IMGT/HLA Database, release 3.22.0, 2015-10-10). Both HLA-DM 
and -DO molecules play a critical role in the HLA classical class 
II ability to functionally bind self and non-self peptides on APC, 
controlling the very first steps of an immune response[57]. HLA-
DM molecules intermediate the process and the affinity of peptide 
binding to HLA classical class II glycoproteins, stabilizing otherwise 
short-lived transition states and promoting rapid peptide exchange 
processes that favours highest-affinity ligands. When classical class 
II molecules assemble in the Endoplasmic Reticulum (ER) the 
peptide binding groove is protected with an invariant chain until this 
complex reach the endosomal peptide loading compartment, where, 
in a stepwise manner, this invariant chain is degraded and HLA-
DM catalyze its substitution by antigenic peptides. Also, the HLA-
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DM molecules have the ability to stabilize empty class II proteins 
and induce dissociation of peptide-binding groove complexes, 
which increases the affinity between classical class II molecules and 
its ligands[58]. HLA-DO molecules also participate in this process 
influencing the repertoire of peptides presented by class II proteins. 
Despite the mechanism by which HLA-DO functions is unclear, it 
binds tightly to HLA-DM and modulates its activity. It seems that 
HLA-DO inhibits HLA-DM function by acting as a substrate mimic 
that prevents HLA class II access[59].
    Among the few non-HLA genes located on class II region, is 
worth mentioning the two TAP (transporter associated with antigen 
processing) genes (TAP1 and TAP2), located between HLA-DOB1 
and -DMB1[18]. For each of both genes 12 alleles were found, being 
TAP1 and TAP2 responsible for expressing 6 and 5 different proteins, 
respectively (IMGT/HLA Database, release 3.22.0, 2015-10-10). 
The two polypeptide chains expressed by TAP genes form a complex 
that pumps degraded cytosolic peptides into the ER lumen to be 
subsequently loaded onto HLA class I molecules[60]. TAP is a member 
of the ATP-binding-cassette (ABC) family of transporters and each 
one of the two molecules that compose the heterodimer includes a 
transmembrane domain (TMD) and a nucleotide-binding domain 
(NBD)[61]. TAP translocates peptides from cytosol into ER under 
consumption of ATP and constitutes an important mechanism in the 
class I peptide-loading complex[62].
    The class III region of the MHC, located between class I and 
class II region, has no known HLA like genes but is the most gene-
dense region in the human genome[63]. The 75 loci that constitute 
this region are responsible for expressing 55 different proteins, 
some of them molecules with an important role on modulating and 
regulating immune response (IMGT/HLA Database, release 3.22.0, 
2015-10-10)[64]. Some of these class III genes that act as critical 
mediators of immunity include tumour necrosis factor (TNF), heat 
shock proteins (HSP), B-associated transcripts (BAT) and some 
complement components loci. For example, C2, CFB, C4B and 
C4A are the complement components genes that are located in 
MHC class III region, belonging to the complement system, part of 
the innate immune system, and made up of several plasma proteins 
that act against pathogens and induce inflammatory responses[65]. 
Also, TNF, located right in the middle of other two class III MHC 
cytokine genes (LTA and LTB), is an important multifunctional 
proinflammatory agent that triggers a cascade of inflammatory 
mediators[66]. Furthermore, 3 HSP genes (HSPA1L, HSPA1A and 
HSPA1B) are also aligned side by side and located within the class 
III region[67]. HSPs act as danger-signalling molecules to the innate 
immune system, showing a regulatory role, namely on natural killer 
cell response to cancer[68]. Additionally, BAT3 gene, one of the 5 
BAT loci intermingled along MHC class III region, has been reported 
to be involved as an immune system mediator in diverse signalling 
pathways, emerging as a new set of immune regulatory proteins 
together with some HSPs and others[69,70].
HLA AND RESPIRATORY INFECTIOUS DISEASES
Since a wide spectrum of respiratory infectious diseases has been 
associated with several genetic markers located in the HLA region, 
we selected, to summarize, analyze and exemplify this topic, those 
with a better established relationship. Also, besides the strictly 
infectious, we included some in which pathogens are mostly 
opportunistic than the main cause of the disease. Thus, pulmonary 
tuberculosis, severe acute respiratory syndrome (SARS), pulmonary 
Mycobacterium avium complex (MAC) infection, idiopathic 
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bonchiectasis, diffuse panbronchiolitis and recurrent respiratory 
papillomatosis were selected to approach and analyse the role of 
HLA loci in respiratory infectious diseases, the aim of this editorial.
Pulmonary tuberculosis
Pulmonary tuberculosis (TB) is a lung infection disease caused by 
Mycobacterium tuberculosis that still causes about 1.5 million deaths 
a year[71]. Despite environmental factors are the leading cause on 
the development of the disease, several studies had shown that host 
genetics also predispose to or protect from TB. Several HLA-DRB1 
alleles have been reported to be related with risk of TB, regardless 
some inconsistency between different ethnic groups[72,73,74]. A recent 
meta-analysis that took in consideration the ethnicity of each case-
control study suggests that, in Asian populations, the DRB1*08: 03 
and HLA-DRB1*15 alleles confer an increased risk of TB, while 
DRB1*03 and DRB1*07: 01 are protective[13]. When including other 
populations besides Asian, namely European and South and North 
American, this same meta-analysis found consistent results with an 
increased risk of TB for individuals with DRB1*08: 03 and HLA-
DRB1*15 alleles. However, in this non-grouping evaluation, besides 
DRB1*03 and the exclusion of DRB1*07: 01, other alleles emerged 
as conferring protection against TB, namely DRB1*11, DRB1*11: 03 
and DRB1*12: 02. Accordingly, in a population from South Africa, 
DRB1*08: 03 allele has found to be strongly positively associated 
with drug-resistance, increase in lung damage and resurgence of 
TB[75]. Another recent meta-analysis including 19 case-control studies 
also confirmed the DRB1*03 protection and DRB1*08 risk effect 
and added DRB1*04 and DRB1*16 as markers associated with an 
increased infection occurrence, concluding also that both ethnicity 
and genotyping methods affect the association between several 
HLA-DRB1 alleles and TB occurrence[76]. Confirming DRB1*04, 
DRB1*15 and DRB1*16, and adding DRB1*09 and DRB1*10 as 
polymorphisms that may contribute to the risk of TB, especially 
in East Asian, and identifying DRB1*11 as conferring protection, 
a 31 studies meta-analysis fail to support a significant association 
between the HLA-DRB1*01, *03, *07, *08, *12, *13, and *14 gene 
polymorphisms and TB risk[77]. Regardless the strong evidences of 
the association with these DRB1 alleles, it’s still unknown whether 
if they influence directly TB susceptibility, namely through the 
ability to present M. tuberculosis antigens to CD4+ T-helper cells, 
or if it results from an indirect influence through other factors. From 
the results available, the heterogeneity that arose on the association 
between TB and DRB1 alleles seems to be a consequence of different 
effects exerted by genetic polymorphisms among each ethnicity, 
namely due to specific variations in gene-environment and gene-gene 
interactions[13,78].
    Other HLA loci were also found to be associated with risk and 
protection for TB. For example, in South India, besides HLA-
DRB1*15: 01, HLA-DQB1*06: 01 were identified as conferring risk 
to TB, together with HLA-DPB1*04 as a marker for protection[79]. 
Also, two studies in Cambodia confirmed DQB1*06: 01 and adds 
DQB1*05: 03 alleles as risk factors for TB[80,81]. Thus, up to date 
studies with HLA high resolution throughput, well defined disease 
pathogenesis, pathogen diversity, higher sample sizes, vaccination 
status information, environmental factors characterization, 
consistent statistics and sharply defined ethnicities are needed to 
better understand the relationship between HLA loci alleles and 
TB susceptibility. Also, the role played by gene-gene interactions 
(epistasis) in TB susceptibility level, namely with non-HLA loci as 
UBE3A, VDR, IL12, IL12RB1, INFG, MBL, SFTPA1/2, MCP1 and 
NRAMP1, could be a contribution to enlighten this subject[82].
    Since TB is the commonest opportunistic infection affecting HIV 
patients as also their leading cause of death, it worth mention that 
certain HLA polymorphisms have been identified as susceptibility 
factors to the infection and progress of TB in HIV[83]. HLA-B*57, 
due to its ability to enhance the presentation of antigenic peptides 
on the surface of HIV-1 infected CD4+ cells to cytotoxic CD8+ 
T cells, has been commonly associated with a suppression of the 
disease progression[84]. In a sample of HIV infected from North India, 
HLA-DRB1*13, -DRB5, -DQB1*06 and -B*15 allelic groups were 
associated with an increase in the risk for TB but -DQB1*06 and 
-B*51 with a protection effect[85]. In a similar study but with samples 
from South India, the HLA haplotype DRB1*15: 02-DQB1*06: 01-
DPB1*02: 01 revealed to increase the risk of TB in HIV infected and, 
in the opposite direction, the HLA-DPB1*15: 01 allele as conferring 
protection[86].
    TNF locus, located in the MHC class III region and coding for 
an important multifunctional cytokine that triggers a cascade of 
inflammatory mediators, has been linked with an increase risk for TB. 
Two mutations in the promoter region of the TNF-α gene at positions 
–238 (G/A) and –308 (G/A) were associated with pulmonary TB in 
the Colombian population[87], the former also confirmed for Iranian 
in two different studies[88,89]. Also, the susceptibility for a pulmonary 
tuberculosis infection was found to be associated with the TNF-α 
-857T/C genetic polymorphism in Asian populations[90] and, for a 
reduced risk, with the CD14 G(-1145)A and C(-159)T polymorphisms 
in Chinese Han population[91]. However, no association was observed 
between TNF polymorphisms and TB in several other populations, 
such Indian, Cambodian, Thais or Turkish[92-95]. Additionally, the use 
of TNF inhibitors in therapies against autoimmune diseases, such 
as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, 
psoriatic arthritis and psoriasis, has been associated to an increase in 
TB risk[96,97].
Severe Acute Respiratory Syndrome (SARS)
The Severe Acute Respiratory Syndrome (SARS) coronavirus 
infection, presenting itself as an atypical pneumonia, is a highly 
contagious disease with high incidence and mortality rates. After 
SARS outbreak in Asia in the beginning of 2003, a few studies have 
been showing that HLA profile correlates with the infection. Right 
on the year of the outbreak, a study with a few dozens of SARS 
patients indicated an association of the HLA-B*46: 01 allele with the 
severity of the infection in Taiwanese population[14]. Later, a case-
control study in the same population revealed that the HLA-C*15: 
02 and -DRB1*03: 01 alleles confer resistance against SARS 
infection[98]. Nevertheless, a cohort of 95 SARS-recovered patients 
from Guangdong, southern China, miss to show any association 
between the development of the disease and their HLA profile[99], 
despite a study with 90 Chinese patients from Hong Kong confirmed 
the HLA-DRB1*03: 01 as a protective allele and unveiled another 
risk allele, the HLA-B*07: 03, despite not confirming the B*46: 
01[100]. Evidences of the SARS-HLA correlation has also been 
found in Vietnamese population, with the HLA-DRB1*12: 02 allele 
showing to be significantly much more prevalent in the patients than 
in control group[101]. Regardless SARS affected several thousands 
of people along the year 2003, the number of samples included in 
the above studies were very low which, together with a suddenly 
decrease on the interest of the subject since the outbreak was 
contained, left to be explored the involvement of the HLA markers 
in the pathogenesis of the disease. Thus, understanding the genetic 
risk or protection conferred by HLA markers on the SARS infection 
requires enlightenment on their contribution for the control of viral 
host defence. However, in half of the cases, the underlying aetiology 
is unknown (idiopathic bronchiectasis) and, in such situations, 
there are bilateral, predominantly lower-lobe disease and chronic 
rhinosinusitis[110]. Despite poorly understood, the progression of 
idiopathic bronchiectasis in the lungs is believed to result from an 
interaction between chronic bronchial infections and a deregulated 
process of inflammation, whatever one or another to be the 
responsible for triggering the process[111].
    HLA region hosts some of the candidate genes that have been the 
focus for genetic studies on idiopathic bronchiectasis. After HLA class 
I antigen deficiency due to a TAP2 gene mutation has been shown 
to be associated with familial bronchiectasis and that bronchiectasis 
affects 80% of patients with primary immunodeficiency resulting 
from defective TAP complex, a couple of studies have been 
developed considering that HLA could be in the core origin of the 
idiopathic cases[112,113]. A HLA class II polymorphism analysis in 
a UK Caucasian disease cohort showed a significant association 
between the haplotype HLA-DRB1*01: 01-DQA1*01-DQB1*05: 
01 and the development of idiopathic bronchiectasis, suggesting the 
implication of the CD4+ T cells in the lung damage underlying the 
disease[114]. Despite not confirmed in a replication study published by 
other authors[115], HLA-C*03 allelic group was found to be associated 
with an increased risk for idiopathic bronchiectasis in British patients, 
and C*06 with a reduced risk[116]. Also, this same study found a 
distinct distribution of the serologically HLA-C groups 1 (Ser-77/
Asn-80) and 2 (Asn-77/Lys-80), with a higher prevalence of HLA-C 
group 1 homozygosity among patients than controls. These findings 
and previous knowledge on the interplay between HLA-C and KIR 
genes, together with the implication of TAP deficiency syndrome, 
suggests a role for NK cells in Bronchiectasis pathology.
    The need for further investigation in HLA implications for 
idiopathic bronchiectasis is evident since little has been done so far. 
TAP deficiencies and HLA expression needs to be evaluated as also if 
HLA implications for the disease influence susceptibility to specific 
pathogens or to self-reactivity, or both. More, large and different 
population studies are also needed to enlighten this subject. 
Diffuse panbronchiolitis
Diffuse panbronchiolitis (DPB) is an inflammatory disease of 
unknown aetiology affecting primarily the respiratory bronchioles 
and causing a severe and chronic obstructive pulmonary disease. DPB 
is commonly associated with recurrent respiratory tract infection and 
reach its highest prevalence among East Asians, especially Japanese, 
affecting males twice than females and, if left untreated, progressing 
to bronchiectasis, respiratory failure and death[117,118]. 
    Ready after it has been described and named in the 1960s, a 
genetic association was suspected, namely due to the identification 
of familial cases, and in 1990 a study with a few dozens of patients 
identified, by serologic means, the HLA-B*54 allelic group (Bw54) 
has being strongly positively associated with the disease[119,120,121]. 
Since this allelic group is characteristic for Asian populations it, at 
least partly, explains why the disorder is found primarily in Asians, 
and raises the suspicion that the genetic predisposition for DPB has 
a major contribution from HLA or from a closely linked gene in 
the region. Since then, other studies confirmed and extended this 
association. The HLA high resolution typing revealed that the B*54: 
01 was the allele of the B*54 group responsible for the association 
and that other B alleles, also belonging to the broad serologic group 
B22, were involved, namely B*55: 04 and B*56: 01[122]. Interestingly, 
the same study found that when taking together the alleles that code 
for the B22 antigen family, and even more when including the related 
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proliferation, on their participation in autoimmune pathogenesis and 
even if there is a link between them and other unknown determinates 
that influence directly the course of SARS infection and the 
associated lung damage[100]. 
Pulmonary MAC infection
The Pulmonary Mycobacterium avium complex (MAC) infection 
is caused by M. avium and M. intracellulare, two nontuberculous 
mycobacteria. Despite ubiquitous in the environment, MAC 
infections occur rarely in immunocompetent hosts, affecting mostly 
those with depressed immunity or with underlying lung diseases[102]. 
MAC is the most common cause of lung nontuberculosis and its rate 
of infection is globally increasing, especially in Japan[103]. Besides 
environmental risk factors, genetic susceptibility to the disease have 
been reported, some of them linked to MHC loci. In fact, through a 
genome wide case-control approach followed by functional analysis 
of the gene expression, MICA, a non-HLA gene located on class 
I region, has been selected in Japanese patients as a promising 
candidate that might be involved in susceptibility to pulmonary 
MAC disease[104]. Especially in female patients, D6S0009i MICA 
polymorphism (MICA-TM), and particularly its A6 allele, has been 
found in the above study has conferring genetic susceptibility to 
MAC. Also, since TNF locus, located in class III MHC region, is an 
important multifunctional proinflammatory agent, some therapies, 
especially in autoimmune diseases such as rheumatoid arthritis, 
uses TNF inhibitors which have been associated to an increased 
risk for MAC and other non-tuberculosis mycobacteriosis, besides 
TB mentioned above[105]. Despite with inconclusive results, other 
studies suggest that specific HLA alleles could be associated with the 
development of pulmonary MAC infection. In a 59 Japanese patients 
sample, the HLA-A*33 and -DRB1*13/14 (DR6) alleles, together 
with the haplotype A*33-B*44-DRB1*13/14(DR6), were found to 
be associated with the infection[106]. Another article published in the 
same year (2000) with 64 Japanese patients confirms the association 
of the HLA-DRB1*13/14 (DR6) alleles to a higher risk of MAC 
infection and adds also HLA-DQB1*04/DQA1*03/04 (DQ4) 
and -A*26, this former especially in the deterioration of nodular-
bronchiectatic MAC infection[107]. A most recent publication (2009) 
evaluating 48 Korean patients with MAC lung disease has found a 
higher susceptibility among the HLA-B*46 carriers[108].
    These mostly inconclusive and inconsistent results on the HLA 
association with MAC infection could be deeply related to the 
low number of studies on the subject, mostly limited to Japanese 
population, with low sample numbers and low resolution HLA 
typing. To mitigate this, new studies need to be done with higher 
sample numbers and discriminating between immunocompetent, with 
depressed immunity and underlying lung diseases hosts. Also, four 
digits high resolution HLA typing studies for a most diverse panel of 
world populations, Asian and others are mandatory to enlighten the 
subject. 
Idiopathic bronchiectasis
Bronchiectasis is a pathological end-point of different mechanisms 
and describes a permanent dilation of the bronchi and bronchioles 
due to the destruction of the muscles and elastic tissues. This lungs 
condition starts with a narrowing of the bronchial tree which may 
lead, if it becomes chronic, to destruction of the epithelium and, 
with the consequent deficient mucociliary clearance, the retention of 
secretions giving way to recurrent infections[109]. The pathological 
processes leading to Bronchiectasis include infectious damage, 
genetic mutations, autoimmune diseases or, among others, unbalance 
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B7 serotype, the positive association with the disorder gets stronger. 
Other HLA were found to be associated, despite weekly, with the 
disease, namely A11 and C1 antigens with a positive association 
and, contrariwise, A33 and B44 antigens, and HLA-DRB1*13: 02 
allele, with a negative association. However, Keicho and colleagues 
(1998) note that these alleles constitute typical haplotypes observed 
among Japanese which, thus, may mean that these other genes 
associations could be only the result of their linkage disequilibrium 
with HLA-B*54 and -B*44.
    An evaluation of HLA in Korean patients showed a positive and 
strong association of the A11 and B55 serotypes with DPB, and 
also with B62 and Cw4 but weaker[123]. Remarkable much stronger 
positive associations with the disease were found when considering 
haplotypes that includes A11, B55 and B62 (A11-Cw1: OR = 12.1, 
Cw1-B55: OR = 9.8, A11-B62: OR = 7.9) rather than each serotype 
itself. Similarly to Japanese population, this study with Koreans 
identified HLA-DR*13 as a protective genetic marker against DPB. 
The rarity of the disease and the subsequent studies low sample 
number adds great difficulties to obtain conclusive results in others 
than Japanese population, but positive association with DPB were 
confirmed in Chinese patients for HLA-A*11 and -B*54[124,125,126]. 
Considering the data available on the association between HLA 
and DPB, some authors hypothesized that the candidate gene(s) 
responsible for the disease susceptibility should be located within 
HLA class I region, most probably between HLA-A and HLA-B 
loci[123,127]. Attempts to narrow the location of this hypothetical 
susceptibility gene(s) have been done and the results obtained 
indicate that it is probably located within a 200 kb segment located 
in the class I region 300 kb telomeric from HLA-B locus[128]. In 
this narrowed region, a mucin-like gene cluster were identified and 
some polymorphisms in one of its genes, the panbronchiolitis related 
mucin-like 1 (PBMUCL1), were found to be associated with the 
disorder, making it a new candidate gene for DPB susceptibility[129].
Recurrent respiratory papillomatosis
Recurrent respiratory papillomatosis (RRP) is a rare but life-
threatening disease characterized by the growth of multiple 
benign tumours in the larynx and other sites within the upper 
aerodigestive[130]. RRP is caused by human papillomavirus (HPV) 
infection but, despite the virus carriage rate in the oropharynx 
is at least 10%, few of the infected develop the disease, which 
indicates that other factors must contribute to the pathogenesis[131,132]. 
Some studies have reported an association between HLA and the 
development of the disease. In 1994, Bonagura and colleagues 
noted that HLA-DQ3 and -DR11 molecules were highly enriched 
in peripheral blood and that HLA class I antigens expression on 
papilloma tissue was markedly reduced in patients with RRP[133]. 
Later, they found a co-down-regulation of TAP1 and HLA class-I in 
respiratory papillomas compared with normal respiratory epithelial 
tissue and that the patients with the most aggressive and rapidly 
progressive disease expressed the lowest levels of TAP1[134]. Since 
TAP translocates peptides from cytosol into ER and constitutes an 
important mechanism in the class I peptide-loading complex, the 
authors of these studies suggest that the resultant absence of surface 
HLA class-I molecules would prevent the recognition of HPV 
peptides at the cell membrane and, consequently, an effective action 
of the immune system.
    Also, an investigation with British patients identified an association 
between the presence of the HLA-DRB1*03: 01 allele and the 
susceptibility to RRP, as also to its severity. This same study  found 
preliminary evidences for an HLA-DRB1*14 association in juvenile-
onset disease and a HLA-B*27 association in adult-onset disease[135]. 
Another study confirmed the association between HLA-DRB1*03: 
01 and the severity of the disease in Caucasian patients and found 
also a positive association with DRB1*01: 02, DQB1*02: 01 and 
DQB1*02: 02 and a protective effect for DQB1*06: 02[136]. In Korean 
patients HLA-DRB1*11: 01 and -DQB1*03: 01, together with 
DRB1*11: 01-DQB1*03: 01 haplotype, were strongly associated to 
severe RRP[137].
CONCLUSION 
The respiratory tract, being an outside open system, is subject to 
frequent contact with a wide diversity of bacteria and virus. The 
ability of the human respiratory system to halt the invasion and 
proliferation of pathogens, and prevent an infection to install is based 
in an all complex innate and adaptive immune system in which an 
extensive arsenal is involved. These immune mechanisms range 
from physical barriers and antimicrobial compounds to immune 
receptors that lead to production of cytokines and chemokines, which 
may affect microorganisms directly and recruit immune cells[7]. The 
complexity and multiplicity of the apparatus and pathways involved 
in the immune response are defined and organized by a highly diverse 
genetic basis. Thus, on the development of respiratory infectious 
diseases, host genetics are obviously well positioned to play an 
important and defining role, influencing the organism ability, more or 
less effective, to oppose to any outside aggression[8,9].
    To date, most studies on HLA association with respiratory 
infectious disease share the same handicap: a low sample number. 
The rarity of some of these pathologies, especially when we consider 
well genetically defined populations, makes difficult the enlargement 
of sample number. Also, increasing even more the difficulties to 
assemble a greater sample number is the variability of aetiologies 
that can be on the basis of each one of these pathologies. Despite the 
available conflicting results and the need for further, larger and better 
studies, it is evident that respiratory infectious disease susceptibility 
is strongly dependent on the individual and collective gene pool. 
Among these genetic factors, HLA loci play a central role despite, 
also here, research is needed to enlighten present knowledge. So far, 
this field has been mostly centred in studies of association which have 
shown a high number of HLA alleles with either risk or protective 
effect. The specific HLA alleles implicated in the susceptibility for 
respiratory infectious disease constitute a highly diverse set, varying 
accordingly with the pathogen involved and, for the same disorders, 
between different human populations. On these HLA and respiratory 
infectious disease associations two different pictures seem to emerge: 
a directly implication of the HLA alleles or an association through 
a close linkage with other loci that may be the direct cause. One or 
another could be the basis for the HLA associations that have been 
found in several populations, depending on the respiratory infectious 
disease considered. In this unclear involvement of HLA loci, gene-
gene and gene-environment interactions could be present, making 
even more difficult a comprehensible analysis of the results obtained 
on the studies. Additionally, besides the influence of a more or 
less effectiveness of the HLA portfolio to signalling the invading 
pathogens, the evolution and installation of respiratory infections 
could also depend on immune cross-reactivity between self and 
non-self antigens that cause inflammatory conditions among which 
opportunistic pathogens proliferate.
    Also, to be taken in consideration in the analysis of the high 
variability found for different populations on the same disease 
HLA association, is the possibility that this inconsistency, besides 
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    A new step forward on the HLA association with respiratory 
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in future studies. Besides the above considerations, HLA studies 
need to be done with DNA high resolution techniques in order to 
assure a four digits typing. However, high resolution data should be 
also analyzed in the context of their serologic meaning, especially 
grouping antigens through their families and functions. The need to 
enlarge the picture of possible mechanisms and pathways involved in 
the aetiology of the respiratory infectious disease requires the study 
of new DNA markers along the MHC region, including HLA and 
non-HLA loci as also segments showing linkage with the already 
identified genetic markers. 
CONFLICT OF INTERESTS 
The author has no conflicts of interest to declare.
REFERENCES 
1 Respiratory disease. In Encyclopædia Britannica. Retrieved from 
http: //www.britannica.com/science/respiratory-disease in 15th 
October 2015.
2 Putra AC, Tanimoto K, Syahruddin E, Andarini S, Hosoi Y, 
Hiyama K. A step forward into respiratory genetics: overview 
contribution of genetics in respiratory diseases. Asian Biomedicine 
2012; 6(5): 639-651.
3 Bonsignori F, Chiappini E, De Martino M. The infections of the 
upper respiratory tract in children. Int J Immunopathol Pharmacol 
2010; 23(1Suppl): 16-19.
4 Peden DB, Bush RK. Advances in environmental and occupational 
disorders in 2014. J Allergy Clin Immunol 2015; 136(4): 866-871. 
doi: 10.1016/j.jaci.2015.08.008.
5 WHO. Action Plan of the Global Alliance against Chronic 
Respiratory Diseases 2008-2013. Geneva. World Health 
Organization, 2008. Retrieved from http: //www.who.int/gard/
publications/GARD_actionplan_FINAL.pdf in 25th December 
2015.
6 WHO. The top 10 causes of death. Fact sheet N°310. World 
Health Organization, updated May 2014. Retrieved from http: //
www.who.int/mediacentre/factsheets/fs310/en/ in 18th February 
2016.
7 Parker D, Prince A. Innate immunity in the respiratory epithelium. 
Am J Respir Cell Mol Biol 2011; 45(2): 189-201.
8 Loisel DA, Du G, Ahluwalia TS, Tisler CJ, Evans MD, Myers RA, 
Gangnon RE, Møller EK, Bønnelykke K, Bisgaard H, Jackson 
DJ, Lemanske RF Jr, Nicolae DL, Gern JE, Ober C. Genetic 
associations with viral respiratory illnesses and asthma control in 
children. Clin Exp Allergy 2015 Sep 24. doi: 10.1111/cea.12642.
9 Gonzales-van Horn SR, Farrar JD. Interferon at the crossroads of 
allergy and viral infections. J Leukoc Biol 2015: 98(2): 185-194. 
doi: 10.1189/jlb.3RU0315-099R.
10 Rowell JL, Dowling NF, Yu W, Yesupriya A, Zhang L, Gwinn M. 
Trends in population-based studies of human genetics in infectious 
diseases. PLoS One 2012; 7(2): e25431. doi: 10.1371/journal.
pone.0025431.
11 Patarčić I, Gelemanović A, Kirin M, Kolčić I, Theodoratou E, 
Baillie KJ, de Jong MD, Rudan I, Campbell H, Polašek O. The 
role of host genetic factors in respiratory tract infectious diseases: 
binding suggest unique and interacting functional roles for 
HLA-E, F, and G in maternal-placental immune recognition. J 
Immunol 2003; 171(3): 1376-1384.
30 Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune 
tolerance in pregnancy. FASEB J 2005; 19(7): 681-693.
31 Sullivan LC, Clements CS, Rossjohn J, Brooks AG. The major 
histocompatibility complex class Ib molecule HLA-E at the 
interface between innate and adaptive immunity. Tissue Antigens 
2008; 72 (5): 415-424.
32 Kraemer T, Celik AA, Huyton T, Kunze-Schumacher H, Blasczyk 
R, Bade-Döding C. HLA-E: Presentation of a Broader Peptide 
Repertoire Impacts the Cellular Immune Response—Implications 
on HSCT Outcome. Stem Cells International 2015; Article ID 
346714, 12 pages. http: //dx.doi.org/10.1155/2015/346714.
33 Felício LP, Porto IO, Mendes-Junior CT, Veiga-Castelli LC, 
Santos KE, Vianello-Brondani RP, Sabbagh A, Moreau P, Donadi 
EA, Castelli EC. Worldwide HLA-E nucleotide and haplotype 
variability reveals a conserved gene for coding and 3’ untranslated 
regions. Tissue Antigens 2014; 83 (2): 82-93.
34 Lee N, Llano M, Carretero M, Ishitani A, Navarro F, López-Botet 
M, Geraghty DE. HLA-E is a major ligand for the natural killer 
inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 1998; 
95(9): 5199-5204.
35 Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. 
HLA-E surface expression depends on binding of TAP-dependent 
peptides derived from certain HLA class I signal sequences. The 
Journal of Immunology 1998; 160 (10): 4951-4960.
36 Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. 
Recognition of human histocompatibility leukocyte antigen 
(HLA)-E complexed with HLA class I signal sequence-derived 
peptides by CD94/NKG2 confers protection from natural killer 
cell-mediated lysis. The Journal of Experimental Medicine 1998; 
187(5): 813-818.
37 Pietra G, Romagnani C, Manzini C, Moretta L, Mingari MC. The 
emerging role of HLA-E-restricted CD8+ T lymphocytes in the 
adaptive immune response to pathogens and tumors. J Biomed 
Biotechnol. 2010: 907092. doi: 10.1155/2010/907092.
38 Kraemer T, Blasczyk R, Bade-Doeding C. HLA-E: a novel player 
for histocompatibility. Journal of Immunology Research 2014; 
Article ID 352160, 7 pages.
39 Michaëlsson J, Matos CT, Achour A, Lanier LL, Kärre K, 
Söderström K. A signal peptide derived from hsp60 binds HLA-E 
and interferes with CD94/NKG2A recognition. The Journal of 
Experimental Medicine 2002; 196 (11): 1403-1414.
40 Lee N, Ishitani A, Geraghty DE. HLA-F is a surface marker on 
activated lymphocytes. Eur J Immunol 2010; 40: 2308-2318. doi: 
10.1002/eji.201040348.
41 Xu Y, Han H, Zhang F, Lv S, Li Z, Fang Z. Lesion human 
leukocyte antigen-F expression is associated with a poor prognosis 
in patients with hepatocellular carcinoma. Oncology Letters 2015; 
9(1): 300-304. doi: http: //doi.org/10.3892/ol.2014.2686.
42 Lee N, Geraghty DE. HLA-F surface expression on B cell and 
monocyte cell lines is partially independent from tapasin and 
completely independent from TAP. J Immunol 2003; 171(10): 
5264-5271.
43 Goodridge JP, Burian A, Lee N, Geraghty DE. HLA-F complex 
without peptide binds to MHC class I protein in the open 
conformer form. J Immunol 2010; 184(11): 6199-6208.
44 Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, 
Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance 
to tissue acceptance. Adv Immunol 2003; 81: 199-252.
45 Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella 
ED. Direct evidence to support the role of HLA-G in protecting 
the fetus from maternal uterine natural killer cytolysis. Proc Natl 
Acad Sci USA 1997; 94: 11520-11525.
46 Rouas-Freiss N, Moreau P, LeMaoult J, Carosella ED. The 
Dual Role of HLA-G in Cancer. Journal of Immunology 
63
Spínola H. HLA and respiratory infections
Research 2014; Article ID 359748, 10 pages. doi: http: //dx.doi.
org/10.1155/2014/359748.
47 Rouas-Freiss N, Moreau P, Menier C, LeMaoult J, Carosella ED. 
Expression of tolerogenic HLA-G molecules in cancer prevents 
antitumor responses. Seminars in Cancer Biology 2007; 17(6): 
413-421.
48 Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, 
Burg G, Stahel RA, Dummer R, Trojan A. Human leukocyte 
antigen G up-regulation in lung cancer associates with high-grade 
histology, human leukocyte antigen class I loss and interleukin-10 
production. American Journal of Pathology 2001; 159(3): 817-
824.
49 Collins RW. Human MHC class I chain related (MIC) genes: their 
biological function and relevance to disease and transplantation. 
Eur J Immunogenet 2004; 31(3): 105-114.
50 Champsaur M, Lanier LL. Effect of NKG2D ligand expression on 
host immune responses. Immunol Rev 2010; 235(1): 267-285. doi: 
10.1111/j.0105-2896.2010.00893.x.
51 McCluskey J, Peh CA. The human leucocyte antigens and clinical 
medicine: an overview. Rev Immunogenet 1999; 1(1): 3-20.
52 West MA, Lucocq JM, Watts C. Antigen processing and class II 
MHC peptide-loading compartments in human B-lymphoblastoid 
cells. Nature 1994, 369 (6476): 147-151.
53 Zhu J, Paul WE. Peripheral CD4+ T-cell differentiation regulated 
by networks of cytokines and transcription factors. Immunol Rev 
2010; 238(1): 247-262.
54 Traherne JA. Human MHC archi tecture and evolut ion: 
implications for disease association studies. Int J Immunogenet 
2008; 35: 179-192.
55 Morris P, Shaman J, Attaya M, Amaya M, Goodman S, Bergman C, 
Monaco JJ, Mellins E. An essential role for HLA-DM in antigen 
presentation by class II major histocompatibility molecules. 
Nature 1994; 368 (6471): 551-554.
56 Tonnelle C, DeMars R, Long EO. DO beta: a new beta chain gene 
in HLA-D with a distinct regulation of expression. The EMBO 
journal 1985; 4: 2839-2847.
57 Kropshofer H, Hämmerling GJ, Vogt AB. The impact of the non-
classical MHC proteins HLA-DM and HLA-DO on loading of 
MHC class II molecules. Immunol Rev 1999; 172: 267-278.
58 Pos W, Sethi DK, Wucherpfennig KW. Mechanisms of peptide 
repertoire selection by HLA-DM. Trends Immunol 2013; 34(10): 
495-501. doi: 10.1016/j.it.2013.06.002.
59 Guce AI, Mortimer SE, Yoon T, Painter CA, Jiang W, Mellins ED, 
Stern LJ. HLA-DO acts as a substrate mimic to inhibit HLA-DM 
by a competitive mechanism. Nat Struct Mol Biol 2013; 20(1): 90-
98. doi: 10.1038/nsmb.2460.
60 Schrodt S, Koch J, Tampé R. Membrane Topology of the 
Transporter Associated with Antigen Processing (TAP1) within an 
Assembled Functional Peptide-loading Complex. The Journal of 
Biological Chemistry 2006; 281(10): 6455-6462.
61 Abele R, Tampé R. The ABCs of immunology: structure 
and function of TAP, the transporter associated with antigen 
processing. Physiology (Bethesda) 2004; 19: 216-224.
62 Procko E, Gaudet R. Antigen processing and presentation: 
TAPping into ABC transporters. Curr Opin Immunol 2009; 21(1): 
84-91.
63 Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, 
Khodiyar VK, Lush MJ, Povey S, Talbot CC, Wright MW, Wain 
HM, Trowsdale J, Ziegler A, Beck S. Gene map of the extended 
human MHC. Nat Rev Genet 2004; 5: 889-899.
64 Trowsdale J, Knight JC. Major Histocompatibility Complex 
Genomics and Human Disease. Annu Rev Genomics Hum Genet 
2013; 14: 301-323. doi: 10.1146/annurev-genom-091212-153455.
65 Janeway CA, Travers P, Walport M, Shlomchik M. The 
complement system and innate immunity. In Immunobiology: the 
Immune System in Health and Disease, 2001, 5th edition (New 
York, NY: Garland), 43-64.
66 Fontes FL, Araújo LF, Coutinho LG, Leib SL, Agnez-Lima 
LF. Genetic polymorphisms associated with the inflammatory 
response in bacterial meningitis. BMC Med Genet 2015; 16: 70. 
doi: 10.1186/s12881-015-0218-6.
67 Xie T, Rowen L, Aguado B, Ahearn ME, Madan A, Qin S, 
Campbell RD, Hood L. Analysis of the gene-dense major 
histocompatibility complex class III region and its comparison to 
mouse. Genome Res 2003; 13(12): 2621-2636.
68 Ucisik-Akkaya E, Davis CF, Gorodezky C, Alaez C, Dorak 
MT.HLA complex-linked heat shock protein genes and childhood 
acute lymphoblastic leukemia susceptibility. Cell Stress 
Chaperones 2010; 15(5): 475-485. doi: 10.1007/s12192-009-
0161-6.
69 Goto K, Tong KI, Ikura J, Okada H. HLA-B-associated transcript 
3 (Bat3/Scythe) negatively regulates Smad phosphorylation 
in BMP signaling. Cell Death and Disease 2011; 2: e236; doi: 
10.1038/cddis.2011.114.
70 Bianchi, ME. DAMPs, PAMPs and alarmins: all we need to know 
about danger. J Leukoc Biol 2007; 81: 1-5.
71 WHO. Improved data reveals higher global burden of tuberculosis. 
Geneva, Switzerland: World Health Organization, 2014. Retrieved 
from http: //www.who.int/mediacentre/news/notes/2014/global-
tuberculosis-report/en/ in 20th December 2015.
72 Kuranov AB, Kozhamkulov UA, Vavilov MN, Belova ES, 
Bismilda VL, Alenova AH, Ismailov SS, Momynaliev KT. 
HLA-class II alleles in patients with drug-resistant pulmonary 
tuberculosis in Kazakhstan. Tissue Antigens 2014, 83: 106-112.
73 Mishra G, Kumar N, Kaur G, Jain S, Tiwari PK, Mehra NK. 
Distribution of HLA-A B and DRB1 alleles in Sahariya tribe of 
North Central India: an association with pulmonary tuberculosis. 
Infect Genet Evol 2014, 22: 175-182.
74 Duarte R, Carvalho C, Pereira C, Bettencourt A, Carvalho A, 
Villar M, Domingos A, Barros H, Marques J, Pinho Costa P, 
Mendonça D, Martins B. HLA class II alleles as markers of 
tuberculosis susceptibility and resistance. Rev Port Pneumol 2011; 
17: 15-19.
75 Lombard Z, Dalton DL, Venter PA, Williams RC, Bornman L. 
Association of HLA-DR, -DQ, and vitamin D receptor alleles and 
haplotypes with tuberculosis in the Venda of South Africa. Hum 
Immunol 2006, 67: 643-654.
76 Yang PL, He XJ, Zang QJ, Li HP, Wang GY, Qin J. Association of 
human leukocyte antigen DRB1 polymorphism and tuberculosis: 
a meta-analysis. Int J Tuberc Lung Dis 2016; 20(1): 121-128. doi: 
10.5588/ijtld.14.0930.
77 Tong X, Chen L, Liu S, Yan Z, Peng S, Zhang Y, Fan H. 
Polymorphisms in HLA-DRB1 gene and the risk of tuberculosis: 
a meta-analysis of 31 studies. Lung 2015; 193: 309-318. doi: http: 
//dx.doi.org/10.1007/s00408-015-9692-z.
78 Chen BF, Wang R, Chen YJ, Zhu Y, Ding L, Wen YF. Association 
between HLA-DRB1 alleles and tuberculosis: a meta-analysis. 
Genet Mol Res 2015; 14(4): 15859-15868. doi: 10.4238/2015.
December.1.37.
79 Ravikumar M, Dheenadhayalan V, Rajaram K, Lakshmi SS, 
Kumaran PP, Paramasivan CN, Balakrishnan K, Pitchappan 
RM. Associations of HLA-DRB1, DQB1 and DPB1 alleles with 
pulmonary tuberculosis in south India. Tuber Lung Dis 1999; 
79(5): 309-317.
80 Goldfield AE, Delgado JC, Thim S, Bozon MV, Uglialoro AM, 
Turbay D, Cohen C, Yunis EJ. Association of an HLA-DQ allele 
with clinical tuberculosis. JAMA 1998; 279: 226-228.
81 Goldfield AE. Genetic susceptibility to pulmonary tuberculosis in 
Cambodia. Tuberculosis 2004; 84: 76-81.
82 Schurr E. Is susceptibility to tuberculosis acquired or inherited? J 
Intern Med 2007; 261: 106-111.
83 WHO. World Health Organization: TB/HIV Facts 2015. Retrieved 
from: http: //www.who.int/hiv/topics/tb/tbhiv_facts_2015/en/ in 
21st December 2015.
84 Poropatich K, Sullivan DJ Jr. Human immunodeficiency virus type 
1 long-term non-progressors: the viral, genetic and immunological 
basis for disease non-progression. J Gen Virol 2011; 92(Pt 2): 
247-268. doi: 10.1099/vir.0.027102-0.
85 Saikia B, Wanchu A, Mahakur S, Bind M, Sarkar K, Minz WR. 
Analysis of HLA association among North Indian HIV-positive 
individuals co-infected with Mycobacterium tuberculosis. Lung 
India 2015; 32(5): 449-452. doi: 10.4103/0970-2113.164166.
86 Selvaraj P, Raghavan S, Swaminathan S, Alagarasu K, Narendran 
G, Narayanan PR. HLA-DQB1 and -DPB1 allele profile in HIV 
infected patients with and without pulmonary tuberculosis of 
south India. Infect Genet Evol 2008; 8(5): 664-671. doi: 10.1016/
j.meegid.2008.06.005.
87 Correa  PA, Gomez LM, Cadena J, Anaya JM. Autoimmunity and 
tuberculosis. Opposite association with TNF polymorphism. J 
Rheumatol 2005, 32: 219-224.
88 Merza M, Farnia P, Anoosheh S, Varahram M, Kazampour 
M, Pajand O, Saeif S, Mirsaeidi M, Masjedi MR, Velayati 
AA, Hoffner S. The NRAMPI, VDR and TNF-alpha gene 
polymorphisms in Iranian tuberculosis patients: the study on host 
susceptibility. Braz J Infect Dis 2009; 13(4): 252-256.
89 Jafari M, Nasiri MR, Sanaei R, Anoosheh S, Farnia P, Sepanjnia 
A, Tajik N. The NRAMP1, VDR, TNF-α, ICAM1, TLR2 and 
TLR4 gene polymorphisms in Iranian patients with pulmonary 
tuberculosis: A case-control study. Infect Genet Evol 2016; 39: 92-
98. doi: 10.1016/j.meegid.2016.01.013.
90 Lee YH, Song GG. Associations between tumor necrosis factor-α 
polymorphisms and susceptibility to pulmonary tuberculosis: 
meta-analysis. Genet Mol Res 2015; 14(3): 8602-8612. doi: 
10.4238/2015.July.31.8.
91 Zhao MY, Xue Y, Zhao ZQ, Li FJ, Fan DP, Wei LL, Sun XJ, 
Zhang X, Wang XC, Zhang YX, Li JC. Association of CD14 
G(-1145)A and C(-159)T polymorphisms with reduced risk for 
tuberculosis in a Chinese Han population. Genet Mol Res 2012, 
11(3): 3425-3431. doi: 10.4238/2012.September.25.11.
92 Delgado JC, Baena A, Thim S, Goldfeld AE. Ethnic-specific 
genetic associations with pulmonary tuberculosis. J Infect Dis 
2002; 186: 1463-1468. 
93 Sharma S , Ra thored J , Ghosh B, Sharma SS. Gene t ic 
polymorphisms in TNF genes and tuberculosis in North 
Indians. BMC Infect Dis 2010; 10: 165. doi: http: //dx.doi.
org/10.1186/1471-2334-10-165. 
94 Vejbaesya S, Chierakul N, Luangtrakool P, Sermduangprateep C. 
NRAMP1 and TNF-alpha polymorphisms and susceptibility to 
tuberculosis in Thais. Respirology 2007; 12(2): 202-206.
95 Fol M, Druszczynska M, Wlodarczyk M, Ograczyk E, Rudnicka 
W. Immune response gene polymorphisms in tuberculosis. Acta 
Biochim Pol 2015; 62(4): 633-640. doi: 10.18388/abp.2015_1130.
96 Wiedmann MW, Mössner J, Baerwald C, Pierer M. TNF alpha 
inhibition as treatment modality for certain rheumatologic and 
gastrointestinal diseases. Endocr Metab Immune Disord Drug 
Targets 2009; 9: 295–314.
97 Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatanabodee P, 
Suwannalai P, Hussein H, Rahman MU. Risk of tuberculosis with 
anti-tumor necrosis factor-α therapy: substantially higher number 
of patients at risk in Asia. Int J Rheum Dis 2014; 17(3): 291-298. 
doi: 10.1111/1756-185X.12188.
98 Wang SF, Chen KH, Chen M, Li WY, Chen YJ, Tsao CH, Yen MY, 
Huang JC, Chen YM. Human-leukocyte antigen class I Cw 1502 
and class II DR 0301 genotypes are associated with resistance 
to severe acute respiratory syndrome (SARS) infection. Viral 
Immunol 2011; 24(5): 421-426. doi: 10.1089/vim.2011.0024.
99 Xiong P, Zeng X, Song MS, Jia SW, Zhong MH, Xiao LL, Lan W, 
Cai C, Wu XW, Gong FL, Wang W. Lack of association between 
HLA-A, -B and -DRB1 alleles and the development of SARS: 
a cohort of 95 SARS-recovered individuals in a population of 
Guangdong, southern China. Int J Immunogenet 2008; 35(1): 69-74.
64
Spínola H. HLA and respiratory infections
65
Spínola H. HLA and respiratory infections
100 Ng MH, Lau KM, Li L, Cheng SH, Chan WY, Hui PK, Zee B, 
Leung CB, Sung JJ. Association of human-leukocyte-antigen 
class I (B*0703) and class II (DRB1*0301) genotypes with 
susceptibility and resistance to the development of severe acute 
respiratory syndrome. J Infect Dis 2004; 190(3): 515-518.
101 Keicho N, Itoyama S, Kashiwase K, Phi NC, Long HT, Ha LD, 
Ban VV, Hoa BK, Hang NT, Hijikata M, Sakurada S, Satake M, 
Tokunaga K, Sasazuki T, Quy T. Association of human leukocyte 
antigen class II alleles with severe acute respiratory syndrome in 
the Vietnamese population. Hum Immunol 2009, 70(7): 527-351.
102 Field SK, Fisher D, Cowie RL. Mycobacterium avium complex 
pulmonary disease in patients without HIV infection. Chest 2004; 
126(2): 566-851.
103 Ogawa K, Sano C. Strategies for Mycobacterium avium complex 
infection control in Japan: how do they improve the present 
situation? Kekkaku 2013; 88(3): 355-371.
104 Shojima J, Tanaka G, Keicho N, Tamiya G, Ando S, Oka A, Inoue 
Y, Suzuki K, Sakatani M, Okada M, Kobayashi N, Toyota E, 
Kudo K, Kajiki A, Nagai H, Kurashima A, Oketani N, Hayakawa 
H, Takemura T, Nakata K, Ito H, Morita T, Matsushita I, Hijikata 
M, Sakurada S, Sasazuki T, Inoko H. Identification of MICA 
as a Susceptibility Gene for Pulmonary Mycobacterium avium 
Complex Infection. J Infect Dis 2009; 199(11): 1707-1715. doi: 
10.1086/598982.
105 Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley 
JW, McFarland B, Austin D, Radcliffe L, Suhler E, Choi D, 
Rosenbaum JT, Herrinton LJ. Mycobacterial diseases and 
antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 
72(1): 37-42. doi: 10.1136/annrheumdis-2011-200690.
106 Takahashi M, Ishizaka A, Nakamura H, Kobayashi K, Nakamura 
M, Namiki M, Sekita T, Okajima S. Specific HLA in pulmonary 
MAC infection in a Japanese population. Am J Respir Crit Care 
Med 2000; 162(1): 316-318.
107 Kubo K, Yamazaki Y, Hanaoka M, Nomura H, Fujimoto K, 
Honda T, Ota M, Kamijou Y. Analysis of HLA antigens in 
Mycobacterium avium-intracellulare pulmonary infection. Am J 
Respir Crit Care Med 2000; 161(4 Pt 1): 1368-1371.
108 Um S-W, Ki C-S, Kwon OJ, Koh W-J. HLA Antigens and 
Nontuberculous Mycobacterial Lung Disease in Korean Patients. 
Lung 2009; 187: 136-140.
109 Rademacher J, Welte T. Bronchiectasis—Diagnosis and 
Treatment. Dtsch Arztebl Int 2011; 108(48): 809-815. doi: 
10.3238/arztebl.2011.0809.
110 Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker 
JE, Coulden RA, Flower CD, Bilton D, Keogan MT. An 
investigation into causative factors in patients with bronchiectasis. 
Am J Respir Crit Care Med 2000; 162: 1277–1284.
111 Wilson R, Dowling RB, Jackson AD. The biology of bacterial 
colonization and invasion of the respiratory mucosa. Eur Respir J 
1996; 9: 1523-1530.
112 Donato L, De la Salle H, Hanau D, Tongio MM. Oswald M, 
Vandevenne A, Geisert J. Association of HLA class I antigen 
deficiency related to a TAP2 gene mutation with familial 
bronchiectasis. Journal of Pediatrics 1995; 127(6): 895-900.
113 Gadola SD, Moins-Teisserenc HT, Trowsdale J , Gross 
WL, Cerundolo V. TAP deficiency syndrome. Clinical and 
Experimental Immunology 2000; 121(2): 173-178.
114 Boyton RJ, Smith J, Jones M, Reynolds C, Ozerovitch L, 
Chaudhry A, Wilson R, Rose M, Altmann DM. Human leucocyte 
antigen class II association in idiopathic bronchiectasis, a disease 
of chronic lung infection, implicates a role for adaptive immunity. 
Clin Exp Immunol 2008; 152: 95-101.
115 McDonnell MJ, Anwar GA, Rutherford RM, De Soyza A, Worthy 
S, Corris PA, Lordan JL, Bourke S, Afolabi G, Ward C, Middleton 
P, Middleton D. Lack of association between KIR and HLA-C 
type and susceptibility to idiopathic bronchiectasis. Respir Med 
2014; 108(8): 1127-1133. doi: 10.1016/j.rmed.2014.05.017.
116 Boyton RJ, Smith J, Ward R, Jones M, Ozerovitch L, Wilson 
R, Rose M, Trowsdale J, Altmann DM. HLA-C and Killer 
Cell Immunoglobulin-like Receptor Genes in Idiopathic 
Bronchiectasis. American Journal of Respiratory and Critical 
Care Medicine 2006; 173(3): 327-333. doi: 10.1164/rccm.200501-
124OC.
117 Polet t i V, Casoni G, Chilosi M, Zompatori M. Diffuse 
panbronchioli t is . Eur Respir J 2006; 28 : 862-871. doi: 
10.1183/09031936.06.00131805.
118 Izumi T, Doi O, Nobechi A, Homma Y, Kino N, Nakata K, Inatomi 
K, Homma H. Nation-wide survey of diffuse panbronchiolitis. 
Annual report on the study of interstitial lung disease in 1982. 
Tokyo: Grant-in Aid from the Ministry of Health and Welfare of 
Japan; 1983: 3-41.
119 Yamanaka A, Saiki S, Tamura S, Saito K. Problems in chronic 
obstructive bronchial diseases, with special reference to diffuse 
panbronchiolitis. Naika 1969; 23: 442-451.
120 Sugiyama Y, Kudoh S, Maeda H, Suzaki H, Takaku F. Analysis of 
HLA antigens in patients with diffuse panbronchiolitis. Am Rev 
Respir Dis 1990; 141: 1459-1462.
121 Suzuki M, Usui K, Tamura N, Araki T, Chijimatsu Y, Washizaki M, 
Inatomi K, Homma H. Familial cases of diffuse panbronchiolitis. 
Jpn J Thorac Dis 1981; 19: 645-651.
122 Keicho N, Tokunaga K, Nakata K, Taguchi Y, Azuma A, Bannai M, 
Emi M, Ohishi N, Yazaki Y, Kudoh S. Contribution of HLA Genes 
to Genetic Predisposition in Diffuse Panbronchiolitis. American 
Journal of Respiratory and Critical Care Medicine 1998; 158(3): 
846-850. doi: 10.1164/ajrccm.158.3.9712125.
123 Park MH, Kim YW, Yoon HI, Yoo CG, Han SK, Shim YS, 
Kim WD. Association of HLA class I antigens with diffuse 
panbronchiolitis in Korean patients. Am J Respir Crit Care Med 
1999; 159(2): 526-529. 
124 Tsang KW, Ooi CG, Ip MS, Lam WK, Ngan H, Chan EY, 
Hawkins B, Ho CS, Amitani R, Tanaka E, Itoh H. Clinical profiles 
of Chinese patients with diffuse panbronchiolitis. Thorax 1998; 
53(4): 274-280.
125 She J, Sun Q, Fan L, Qin H, Bai C, Shen C. Association of HLA 
genes with diffuse panbronchiolitis in Chinese patients. Respir 
Physiol Neurobiol 2007; 157(2-3): 366-373.
126 Chen Y, Kang J, Wu M, Azuma A, Zhao L. Differential association 
between HLA and diffuse panbronchiolitis in Northern and 
Southern Chinese. Intern Med 2012; 51(3): 271-276.
127 Keicho N, Hijikata M. Genetic predisposition to diffuse 
panbronchiolitis. Respirology 2011; 16(4): 581-588. doi: 10.1111/
j.1440-1843.2011.01946.x.
128 Keicho N, Ohashi J, Tamiya G, Nakata K, Taguchi Y, Azuma A, 
Ohishi N, Emi M, Park, MH, Inoko H, Tokunaga K, Kudoh S. 
Fine localization of a major disease-susceptibility locus for diffuse 
panbronchiolitis. Am J Hum Genet 2000; 66: 501-507.
129 Hijikata M, Matsushita I, Tanaka G, Tsuchiya T, Ito H, Tokunaga 
K, Ohashi J, Homma S, Kobashi Y, Taguchi Y, Azuma A, Kudoh 
S, Keicho N. Molecular cloning of two novel mucin-like genes in 
the disease-susceptibility locus for diffuse panbronchiolitis. Hum 
Genet 2011; 129(2): 117-128. doi: 10.1007/s00439-010-0906-4.
130 Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope 
2001; 111: 57-69.
131 Ter ry RM, Lewis FA, Gr i ff i ths S , Wel l s M, Bi rd CC. 
Demonstration of human papillomavirus types 6 and 11 in juvenile 
laryngeal papillomatosis by in-situ DNA hybridization. J Pathol 
1987; 153: 245-248.
132 Cason J, Kaye JN, Jewers RJ, Kambo PK, Bible JM, Kell B, 
Shergill B, Pakarian F, Raju KS, Best JM. Perinatal infection and 
persistence of human papillomavirus types 16 and 18 in infants. J 
Med Virol 1995; 47: 209-218.
133 Bonagura VR, Siegal FP, Abramson AL, Santiago-Schwarz F, 
O'Reilly ME, Shah K, Drake D, Steinberg BM. Enriched HLA-
DQ3 phenotype and decreased class I major histocompatibility 
66
Spínola H. HLA and respiratory infections
complex an t igen expres s ion in r ecu r ren t r e sp i r a to ry 
papillomatosis. Clin Diagn Lab Immunol 1994; 1: 357-360.
134 Vambutas A, Bonagura VR, Steinberg BM. Altered Expression 
of TAP-1 and Major Histocompatibility Complex Class I in 
Laryngeal Papillomatosis: Correlation of TAP-1 with Disease. Clin 
Vaccine Immunol 2000; 7(1): 79-85. doi: 10.1128/CDLI.7.1.79-
85.2000.
135 Gelder CM, Williams OM, Hart KW, Wall S, Williams G, Ingrams 
D, Bull P, Bunce M, Welsh K, Marshall SEF, Borysiewicz L. 
HLA Class II Polymorphisms and Susceptibility to Recurrent 
Respiratory Papillomatosis. J Virol 2003; 77(3): 1927-1939. doi: 
10.1128/JVI.77.3.1927-1939.2003.
136 Bonagura VR, Vambutas A, DeVoti JA, Rosenthal DW, Steinberg 
BM, Abramson AL, Shikowitz MJ, Gjertson DW, Reed EF. 
HLA alleles, IFN-gamma responses to HPV-11 E6, and disease 
severity in patients with recurrent respiratory papillomatosis. Hum 
Immunol 2004; 65(8): 773-782.
137 Song EY, Shin S, Park KU, Park MH, Sung MW, Kim KH, 
Kwon TK. Associations of HLA-DRB1 and -DQB1 alleles 
with severe recurrent respiratory papillomatosis in Korean 
patients. Hum Immunol 2013; 74(8): 961-964. doi: 10.1016/
j.humimm.2013.04.020.
